Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
Holding GERN?
Track your performance easily
GERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $5.34
Previous Close$4.28
Volume6.56M
Average Volume (3M)9.25M
Market Cap
$2.73B
Enterprise Value$2.30B
Total Cash (Recent Filing)$362.73M
Total Debt (Recent Filing)$87.04M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 06, 2024EPS Estimate
-$0.09Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding602,795,563
10 Day Avg. Volume8,832,458
30 Day Avg. Volume9,254,903
Standard Deviation0.18
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)9.23
Price to Sales (P/S)2067.86
Price to Cash Flow (P/CF)-13.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.68K
Enterprise Value/Gross Profit9.72K
Enterprise Value/Ebitda-11.12
Forecast
1Y Price Target
$7.50Price Target Upside65.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Geron News
PremiumPre-Earnings
Is GERN a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Commercial OutlookManagement is observing high (80%+) levels of awareness and enthusiasm for Rytelo from both prescribers and payors, fueling confidence in a steady cadence of sales growth in the quarters ahead.
Drug Approval And SalesGERN’s recently approved Rytelo (imetelstat) is a blockbuster drug in the making based on its attractive clinical profile in lower-risk myelodysplastic syndrome (LR-MDS).
Market Potential And AdoptionRytelo's recent adoption within NCCN treatment guidelines boosts confidence in its market potential.
Bears Say
Financial PerformanceRevenue dynamics will depend on patients remaining on therapy.
Management ChangesChief Commercial Officer Anil Kapur will be leaving the firm to pursue other interests.
Management StabilityThe commercial strategy remains intact despite the recently announced departure of Chief Commercial Officer.
---
Ownership Overview
1.74% Insiders
11.64% Mutual Funds
52.06% Other Institutional Investors
34.56% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Currently, no data Available
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 06, 2024 which is in 43 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 08, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.103 by $0.003.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -$0.09.
How many shares outstanding does Geron Corp have?
Geron Corp has 602,795,600 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.103. Following the earnings report the stock price went up 0.877%.
Which hedge fund is a major shareholder of Geron Corp?
Among the largest hedge funds holding Geron Corp’s share is RA Capital Management. It holds Geron Corp’s shares valued at 196M.
---
Geron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (65.38% Upside)
$7.50 (65.38% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 19.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.06%
12-Months-Change
Fundamentals
Return on Equity
-72.56%
Trailing 12-Months
Asset Growth
8.21%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q2 2024
0:00 / 0:00
---
GERN Stock 12 Month Forecast
Average Price Target
$7.50
▲(65.38% Upside)
Technical Analysis
Best Analysts Covering GERN
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+49.05%
reiterated a buy rating 2 months ago
Copying Gil Blum's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +49.05% per trade.
---